News | VIVA | October 05, 2020

The Latest Vascular Interventional Clinical Data Presented at VIVA 2020

Top 10 trials listed below will be presented live

The Latest Vascular Interventional Clinical Data Presented at VIVA 2020 late-breaking sessions

October 5, 2020 — The Vascular Interventional Advances (VIVA) virtual conference will feature 10 late-breaking clinical trials sessions during the virtual meeting Nov. 6-7, 2020. A multidisciplinary, international panel of expert physicians, scientists and regulators will ask questions and shed light on the lasting impact of the research results as they are presented for the first time. 

For more information: https://vivaphysicians.org/clinical-trials

Friday, Nov. 6, 
Session beginning at 11 a.m. PT

   • 5-Year Outcomes from the IN.PACT Global Study. Presented by Thomas Zeller, M.D., Ph.D.

   • Drug-Coated Devices & Limb Outcomes After Endovascular Peripheral Artery Revascularizations. Presented by Connie N. Hess, M.D., MHS.

   • Standard vs Ultrasound-Assisted Thrombolysis for Submassive Pulmonary Embolism. Presented by Efthymios Avgerinos, M.D., Ph.D., MSc.

   • VIVO Study 12-Month Endpoint Results. Presented by Anthony Comerota, M.D.

   • PROMISE I 1-Year Results. Presented by Daniel Clair, M.D.

Saturday, Nov. 7 
Session beginning at 7 a.m. PT

   • DISRUPT PAD III RCT Acute Results: IVL vs PTA in Severe Calcium. Presented by William A. Gray, M.D.

   • REALITY Study: Directional Atherectomy Vessel Preparation Prior to DCB Angioplasty. Presented by Krishna Rocha-Singh, M.D.

   • 24-Month Outcomes from the DETOUR 1 Trial for Percutaneous Femoropopliteal Bypass. Presented by Ehrin Armstrong, M.D.

   • 2-Year Outcomes of a Multi-Centre Study on Infrapopliteal Bioresorbable Vascular Scaffold. Presented by Steven Kum, M.D.

   • 4-Year DCB Mortality Across ILLUMENATE RCTs. Presented by Sean Lyden, M.D.

 

Related VIVA Conference Content:

VIVA 2019 Late-breaking Clinical Trials

Other VIVA news

Related Content

News | Cardiovascular Clinical Studies

July 22, 2022 — BioSig Technologies, Inc. a medical technology company advancing electrophysiology workflow by ...

Home July 22, 2022
Home
News | Cardiovascular Clinical Studies

July 18, 2022 — scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that ...

Home July 19, 2022
Home
News | Cardiovascular Clinical Studies

July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details ...

Home July 15, 2022
Home
News | Cardiovascular Clinical Studies

July 11, 2022 — Smoking traditional or non-combustible cigarettes while wearing a surgical mask results in a two-fold ...

Home July 12, 2022
Home
News | Cardiovascular Clinical Studies

June 24, 2022 — Henry Ford Health was part of a multi-institutional heart failure study that was launched and executed ...

Home June 24, 2022
Home
News | Cardiovascular Clinical Studies

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and ...

Home June 21, 2022
Home
News | Cardiovascular Clinical Studies

June 13, 2022 — Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that ...

Home June 13, 2022
Home
News | Cardiovascular Clinical Studies

June 1, 2022 — Biofourmis, a Boston-based global leader in virtual care and digital medicine, announced that its ...

Home June 01, 2022
Home
News | Cardiovascular Clinical Studies

May 31, 2022 — Findings from the XARELTO (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and ...

Home May 31, 2022
Home
News | Cardiovascular Clinical Studies

May 26, 2022 — For more than 20 years, scientists have known that people with hypertension, diabetes, high cholesterol ...

Home May 26, 2022
Home
Subscribe Now